Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market 2022-2028: Emergence of New Diagnostic Technologies & Growing Number of Pipeline Drugs Presents Opportunities - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.

MARKET OUTLOOK

This report states that the Alzheimer's disease therapeutics and diagnostics market in the Asia-Pacific would fast progress with a CAGR of 12.18% over the forecast duration from 2022 to 2028. Japan, India, South Korea, China, Australia & New Zealand, ASEAN countries, and Rest of Asia-Pacific are assessed in the market in this region.

South Korea's population is aging rapidly. The number of people aged 65 years or above is predicted to reach 12.658 million (24.7%) by 2030, as per the World Population Ageing 2019 study. Due to the rising elderly population's increased susceptibility to neurological illnesses, including Alzheimer's disease, the demand for its therapeutics and diagnostics is expected to surge. As a result, the Alzheimer's disease therapeutics and diagnostics market in the country is anticipated to experience growth during the forecast period.

The Japanese market for Alzheimer's disease diagnostics and therapeutics is also anticipated to grow favorably over the forecast period, thanks to a strong healthcare system to meet the demands of the rapidly growing geriatric population suffering from dementia, as well as effective public policies and dedicated research for introducing novel treatments.

R&D activities for Alzheimer's detection are in full swing, as the overall understanding of the disease pathology has also gained significant momentum in the last few years. The National Clinical Trials Registry (NCT) reports that there are roughly 15 ongoing clinical trials for Alzheimer's disease across various phases at present in the country. Such developments are expected to foster the market's growth.

Market Dynamics

Market Drivers

• Prevalence of Alzheimer's Disease
• Rise in the Elderly Population

Market Challenges

• Failure of Late-Stage Drugs
• Stringent Government Regulations

Market Opportunities

• Emergence of New Diagnostic Technologies
• Growing Number of Pipeline Drugs

Key Topics Covered:

1. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market - Summary

2. Industry Outlook

3. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market - by Therapeutics

4. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market - by Diagnostics

5. Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market - Country Outlook

6. Competitive Landscape

7. Methodology & Scope

Companies Mentioned

• Baxter International Inc
• F- Hoffmann-La Roche AG
• Allergan plc (Acquired by Abbvie)
• Novartis AG
• Pfizer Inc
• Siemens Healthineers AG
• Amarantus Bioscience Holdings Inc
• Eisai Co Ltd
• Eli Lilly & Company
• Lupin Limited
• Merck and Co
• Biogen Inc
• Cognoptix Inc
• GE Healthcare
• Johnson and Johnson
• Sun Pharmaceuticals Industries Ltd
• Teva Pharmaceutical Industries Ltd
• Zydus Cadila

For more information about this report visit https://www.researchandmarkets.com/r/1ax9td

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900